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7 ABSTRACT: The use of selenocysteines and various cross-
8 linkers to induce helicity in a bioactive peptide is described. The
9 higher reactivity of selenocysteine, relative to cysteine, facilitates
10 rapid cross-linking within unprotected linear peptides under
11 mild aqueous conditions. Alkylating agents of variable topology
12 and electrophilicity were used to link pairs of selenocysteines
13 within a p53 peptide. Facile selenoether formation enables
14 diverse tailoring of the helical peptide structure.
15 Stapled peptides are a fast-growing class of bioactive16 peptides that reproduce an α-helix from a protein−protein
17 interaction (PPI). Their ability to bind tightly at shallow PPI
18 interfaces has enabled functional modulation of PPIs
19 considered diﬃcult to target with conventional drugs.1 Rapid
20 synthetic access to peptide helices with diverse components
21 could accelerate the discovery of PPI inhibitors. Here, we
22 describe a new strategy to induce peptide helicity that expands
23 the scope of peptide stapling by cross-linking pairs of
24 selenocysteine (Sec) residues.2 The higher side-chain acidity
25 of Sec vs cysteine (pKa Sec: 5.2−5.6; pKa vs Cys: 8.2; pKa Sec
26 within some peptides: 3−4)2c−e enables more facile reactions
27 with electrophilic alkanes of varying length and reactivity (see
f1 28 Figure 1).
29 Many diﬀerent side-chain to side-chain cross-linking
30 strategies have been reported to induce helical structure in
31 peptides,1,3−5 including C−C bond formation via Ru-catalyzed
32 oleﬁn metathesis,1c,6 lactam-bridging between Lys and Asp,7
33Cu-catalyzed 1,3-dipolar cycloaddition,8,9 and bis-thiolation of
34peptides containing two cysteines.10 Oleﬁn metathesis and
35lactam stapling directly couple side-chains of two amino acids,
36limiting variations to the cross-link.5,11,12 Changing staple
37composition or ﬂexibility often requires elaborate synthesis
38and/or optimization of on-resin cross-linking reactions.6,8 In a
39two-component approach, such as cysteine bis-alkylation (most
40popular)10,13−15 or click-bridging with dialkynyl spacers,9 a
41bifunctional linker is inserted between the two side-chains and
42permits chemical diversity in the staple.3
43However, while connecting cysteine side-chains is simple, it
44is only practical with highly electrophilic linkers; for example, S-
45alkylation with bis-bromomethyl13,14 or bis-haloacetamide16
46aromatic reagents, or SN-arylation with reactive arylhalides such
47as perﬂuoroaryl,15 palladium-aryl,17 and tetrazine18 connectors.
48Less-electrophilic aliphatic cross-linkers such as dibromoalkanes
49or diiodoalkanes fail to alkylate cysteines at pH 8 and 20 °C or
50give low yields13a,19 and require harsher cyclization conditions
51that limit utility. Alternatively, cysteines can be modiﬁed with
52bis-diene linkers via photochemical thiol-ene reactions, but such
53reagents are less accessible than their electrophilic counter-
54parts.20
55Here, we demonstrate facile alkylation under mild conditions
56of two Sec inserted at (i, i + 4); (i, i + 7); or (i, i + 11) positions
57in an unstructured peptide analogue of the tumor suppressor
58p53 (see Figure 1). The sequence is based on a known peptide
59inhibitor (ATSP-7041) of the p53-MDM2 interaction in cancer
60cells.21,22 We investigate the potential of linkers of diﬀering size,
61hydrophobicity, and rigidity to cross-link two Sec residues and
62induce 1−3 helical turns in the peptide.
63Conditions for selenoether formation were investigated by
64preparing a linear peptide Ac-LTFUEYWAQBUSAA-NH2
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Figure 1. Proposed selenoether stapling of p53 mimicking peptide
using diﬀerent dihaloalkanes to cross-link two Sec, leading to α-helical
peptide structures. (B = L-cyclobutylalanine; R = linker.)
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65 (where B = cyclobutylalanine), containing two Sec residues (U)
66 positioned at (i, i + 7) positions, using standard Fmoc-based
67 solid-phase peptide synthesis protocols and Fmoc-Sec(Trt)−
f2 68 OH23 as the Sec building block (see Figure 2A). After cleaving
69 from the resin via acidolysis, the selenide moieties were
70 liberated but, instead of two selenols, they formed an
71 intramolecular diselenide bond, in addition to other diselenide
72 oligomers.2a,24 Adding reducing reagent dithiothreitol (DTT)
73 to crude mixtures increased diselenide monomer 1 that was
74 isolated by reversed-phase high-performance liquid chromatog-
75 raphy (RP-HPLC) (see Figures S1 and S2 in the Supporting
76 Information). To investigate the scope of Se-alkylation with
77 less-electrophilic aliphatic linkers, diselenide 1 was combined
78 with 1,8-dibromooctane (8 equiv) in the presence of DTT (20
79 equiv) in a mixture of DMF and 0.1 M phosphate buﬀer pH 6−
80 8 or NaHCO3. DMF was added to increase the solubility of the
81 precursor peptide. In all cases, 1 was converted to
82 diselenoether-tethered peptide 2 in excellent yield (Figure
83 2B). Although cross-linker was present in excess, it was only
84 added once to the peptide, suggesting rapid ring closure with
85 the second Sec residue. Cross-linking of corresponding
86 cysteines in Ac-LTFCEYWAQBCSAA-NH2 with 1,8-dibro-
87 mooctane gave no or only traces of bis-thioether cross-linked
88 peptide at pH 8.5 (Figure 2C) or under heating25 (see Figure
89 S3 in the Supporting Information).
90 Next, diselenide 1 was reacted with other bis-alkylators under
f3 91 similar neutral conditions (see Figure 3, as well as Figure S4
92and Table S1 in the Supporting Information). Compounds 1,7-
93dibromoheptane and 1,9-dibromononane eﬃciently reacted
94with 1 to give cyclic peptides 3 and 4. The more-reactive 1,2-
95bis(2-iodoethoxy)ethane and 4,4′-bis(bromomethyl)-biphenyl
96similarly produced 5 and 6, but excess electrophile (beyond 2
97equiv) simultaneously alkylated both Sec residues.
98Encouraged by the high eﬃciency of Sec-cross-linking, we
99also investigated cross-linking of Sec residues at (i, i + 4) and (i,
100i + 11) positions. For these series, commercially available
101Fmoc-Sec(Mob)−OH was employed as Sec building blocks
102and subsequent Sec-deprotection occurred with 2,2′-dithiobis-
103(5-nitropyridine) (DTNP) in TFA during resin detachment, as
104previously described.26 To simplify the synthetic protocol and
105improve yields, alkylating reagents were directly reacted with
106crude peptides after cleavage from the resin (see Figure S5 in
107the Supporting Information).2a A range of dichloroalkyl,
108dibromoalkyl, or diiodoalkyl or aryl linkers of diﬀerent length
109and ﬂexibility were used to cross-link Sec residues to form
110 f4macrocyclic peptides 7−17 (see Figure 4, as well as Tables S2
111and S3 in the Supporting Information).
Figure 2. (A) Synthesis of Se-cross-linked peptide 2 via diselenide
precursor 1. Asterisks denote standard side-chain protecting groups.
(B) HPLC analysis of Se-alkylation of 1 (100 μM) with 1,8-
dibromooctane (800 μM) in the presence of DTT (2 mM) in DMF/
0.1 M phosphate buﬀer (PB) (pH 6, 7, or 8) or DMF/0.1 M NaHCO3
(1:1) for 1 h (5 h in pH 6) at 22 °C. The percent conversion of 1 to 2
is shown. Arrows indicate the retention time of 1 and 2. (C) UPLC
analysis showing lack of cross-linking of LTFCEYWAQBCSAA (1
equiv) with 1,8-dibromooctane (2 equiv) in 0.1 M NaHCO3 (pH
8.5):DMF (1:1) for 18 h at 22 °C. No bis-S-alkylation and only traces
of monoalkylated material (peak b) were detected. Since the linear
peptide did not signiﬁcantly oxidize (<8% S−S formation after 18 h,
peak a), no reducing reagent was necessary (i.e., DTT or TCEP).
Figure 3. Alkylation of precursor 1 (100 μM) with 1,7-
dibromoheptane (800 μM), 1,9-dibromononane (800 μM), 1,2-
bis(2-iodoethoxy)ethane (200 μM), or 4,4′-bis(bromomethyl)-
biphenyl (200 μM) in the presence of DTT (2 mM) in DMF/0.1
M PB pH 7 (1:1) for 1 h at 22 °C.
Figure 4. Examples of (i, i + 4) and (i, i + 11) selenoether cross-linked
peptides 7−17. Solid black circles represent Se atoms.
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112 The α-helicity of diselenoether peptides in phosphate buﬀer
113 pH 7.2 was assessed by circular dichroism spectroscopy (see
f5 114 Figure 5). The peptides displayed varying degrees of α-helicity,
115 but are signiﬁcantly higher (2−4 fold), compared to the parent
116 linear sequence Ac-LTFEHYWAQLTS-NH2 (PDI)
22 (Figure
117 5A). The longer alkane linkers showed the highest helix
118 induction for (i, i + 7) constructs (2 and 4; see Figure 5B). For
119 the (i, i + 4) series, helical stabilization was less prominent
120 using alkene- or alkyne-constrained tethers than their aliphatic
121 counterparts; whereas an o-xylene linkage (14) was the most α-
122 helix-inducing aromatic connector of positions Sec8-Sec12,
123 although with accompanying 310-helix formation (Figure 5C).
124 Among (i, i + 11) stapled peptides, the 10-atom-long aliphatic
125 cross-linker in 16 displayed the strongest α-helical stabilization
126 (Figure 5D).
127 MDM2 binding of selenoether peptides with various linkers
128 was evaluated by competition ﬂuorescence polarization assay,
129 where 2−17 competed against MDM2 complexed with a
130 ﬂuorescein-labeled PDI (FITC-PDI). Most cross-linked pep-
131 tides showed enhanced aﬃnity, compared to PDI (1.2−2.5-fold
f6 132 increase for 11 of the 16 stapled peptides; see Figure 6A, as well
133 as Table S4 in the Supporting Information). Next, we examined
134 the ability of the selenoether-stapled peptides to aﬀect viability
135 of MCF-7 breast cancer cells, determined by XTT assay after
136 incubating peptides at 3, 10, and 30 μM concentrations (Figure
137 6B). The control linear peptide PDI showed no activity in this
138 assay. From the (i, i + 7) series, peptides 2 and 4 were the most
139 active and reduced cell viability in a dose-dependent manner.
140 Interestingly, polyethylene glycol (PEG)-stapled peptide 5
141showed moderate activity at 30 μM, indicating that PEGylated
142cross-linked peptides can also penetrate cells and act as PPI
143inhibitors. Compounds of the (i, i + 4) series did not reduce
144cell viability. Peptides 15 and 16 of the (i, i + 11) series showed
145poor solubility in an assay buﬀer and were not tested, while 17
146was soluble but had no signiﬁcant activity (Figure 6B).
147To establish that the reduced cancer cell viability was not a
148consequence of nonspeciﬁc membrane disruption by the
149peptides, we tested the peptides for lysis of healthy human
150red blood cells (RBC). As shown in Figure 6C, octane-cross-
151linked peptide 2 and PEGylated peptides 5 and 17 exhibited no
152signiﬁcant lytic activity in these cells, while the more-
153hydrophobic peptide nonane-cross-linked 4 induced moderate
154RBC lysis at higher μM concentrations.
155We have demonstrated a simple synthetic strategy to rapidly
156construct structurally diverse helix-constrained peptides by
157purposely varying both the positions of two selenocysteine
158residues along the sequence and the composition of the
159aliphatic linker between them. Two-component selenoether
160stapling occurred under mild conditions, in neutral aqueous
161media at room temperature, with unprotected peptide
162precursors that are readily prepared by standard solid-phase
163peptide synthesis. Se-alkylation can be performed under a wider
164pH range than Cys-alkylation and is remarkably eﬀective using
165less-reactive electrophiles such as dichlorobutane and dibro-
166mooctane. At neutral pH, DTT was an eﬀective reductant for
167Sec without signiﬁcantly reacting with electrophilic linkers
168(except for stronger alkylating reagent 1,2-bis(2-iodoethoxy)-
169ethane). Alternatively, Se-alkylation may be performed in the
170presence of ascorbate instead of DTT.27 In this study, we found
171that a modiﬁed peptide epitope constrained at positions 4 and
17211 via a 12-atom aliphatic cross-linker (2) was the most
173promising derivative from a diverse series of bis(selenoether)
174peptides. Considering the abundance of commercially available
Figure 5. (A) α-Helicity (%) of selenoether-cross-linked peptides 2−
17 (50 μM) in 10 mM phosphate buﬀer pH 7.2 (PB) or 10 mM PB:
triﬂuoroethanol (TFE) (1:1) determined by CD spectroscopy. (B−D)
CD spectra of PDI and the two most helical peptides in each series: (i,
i + 7) (panel (B)), (i, i + 4) (panel (C)), and (i, i + 11) (panel (D)) in
10 mM PB (panels (B) amd (C)) or in 10 mM PB:TFE (1:1) (panel
(D)) at 22 °C.
Figure 6. (A) Inhibitory activity of peptides PDI (IC50 = 57.7 ± 4.9
nM), 2 (IC50 = 31.2 ± 0.5 nM), 8 (IC50 = 22.8 ± 0.8 nM), and 15
(IC50 = 37.3 ± 0.9 nM) against a FITC-PDI/MDM2 complex. (B)
Cell viability of MCF-7 cells after incubation at 37 °C with peptides
2−5 and 17 for ﬁve days. Remaining live cells after peptide incubation
were colorimetrically determined by reducing the dye XTT (2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) by
cellular enzymes of damaged cells. (C) Hemolysis of human red
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175 bifunctional electrophilic cross-linkers, the selenoether stapling
176 approach demonstrated here permits facile access to peptide
177 macrocycles of diverse chemical and topological composition
178 that can be explored to ﬁne-tune biophysical properties of
179 peptide inhibitors of diﬀerent PPIs. Such peptides have the
180 promise to target yet undruggable intracellular oncogenic
181 proteins, triggering apoptosis and modulate cancer progres-
182 sion.1 Finally, the Se-stapling approach adds to the growing
183 repertoire of strategic applications of Sec in peptides and
184 proteins, including advances in peptide folding, metabolic
185 stability, intramolecular cyclization, and protein synthesis.2,24,28
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